Eledon Pharmaceuticals, Inc.ELDNNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-26.17%
↓ 257% below average
Average (39q)
16.62%
Historical baseline
Range
High:393.66%
Low:-83.19%
CAGR
+2.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -26.17% |
| Q2 2025 | 49.85% |
| Q1 2025 | -24.53% |
| Q4 2024 | 8.52% |
| Q3 2024 | 63.47% |
| Q2 2024 | 36.38% |
| Q1 2024 | 4.85% |
| Q4 2023 | -10.89% |
| Q3 2023 | 10.14% |
| Q2 2023 | -11.24% |
| Q1 2023 | 11.90% |
| Q4 2022 | -2.71% |
| Q3 2022 | 29.76% |
| Q2 2022 | -13.44% |
| Q1 2022 | 7.33% |
| Q4 2021 | -19.27% |
| Q3 2021 | 80.53% |
| Q2 2021 | -24.96% |
| Q1 2021 | 86.20% |
| Q4 2020 | 393.66% |
| Q3 2020 | -26.08% |
| Q2 2020 | -49.51% |
| Q1 2020 | 23.63% |
| Q4 2019 | -11.66% |
| Q3 2019 | -34.31% |
| Q2 2019 | -23.15% |
| Q1 2019 | 9.09% |
| Q4 2018 | 65.96% |
| Q3 2018 | 24.23% |
| Q2 2018 | 21.15% |
| Q1 2018 | 122.52% |
| Q4 2017 | -4.64% |
| Q3 2017 | -3.00% |
| Q2 2017 | 74.18% |
| Q1 2017 | -70.46% |
| Q4 2016 | -83.19% |
| Q3 2016 | -37.73% |
| Q2 2016 | 24.76% |
| Q1 2016 | 2.56% |
| Q4 2015 | -8.93% |